RoosterBio, a Maryland, US, supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, says the partnership ties in with its aims to expand globally this year and beyond.
“RoosterBio’s engineered media products are creating transformative impact for cell and exosome therapy developers all over the world,” said Tim Kelly, CEO. “One of our key objectives in 2022 is to expand global access to our best-in-class products and services, particularly in Europe and Asia. Some of the most exciting R&D in the MSC and exosome space is being conducted in China, so we have sought to partner with an industry leader in that region.”
In addition to product distribution, the agreement creates an access path to RoosterBio’s process development and analytical services, which help advanced therapy developers move candidates into the clinic. These services, combined with media solutions, 'offers therapy developers a complete solution, addressing upstream expansion of hMSC’s in 2D flasks or 3D bioreactors, optimized conditions for exosome collection, and downstream processes to achieve purity, yield, and potency of the final formulated drug product.'
Tamao Kaku, Managing Director of MBL Beijing (a JSR Life Sciences company supplying products to support life sciences), said: “After evaluating the current solutions available, we determined that drug developers in China will greatly benefit from the RoosterBio technology platform and product portfolio. We are pleased to have the opportunity to support our cell and exosome therapy developers by offering this industry-leading solution.”
MBL Beijing will start accepting and fulfilling RoosterBio orders in September 2022.